Heron Therapeutics (HRTX) vs PDS Biotechnology (PDSB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
PDS Biotechnology (PDSB) has outperformed Heron Therapeutics (HRTX) over the past year, gaining 2.0% versus a loss of 73.5%. Over five years, PDSB leads with a -91.7% price change compared with -96.6% for HRTX. PDS Biotechnology is the larger company by market cap ($73.9 million vs $68.0 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HRTX | PDSB |
|---|---|---|
| Share price | $0.3582 | $1.02 |
| Market cap | $68.01M | $73.92M |
| 1-day change | -6.79% | -4.23% |
| YTD return | -72.45% | +32.47% |
| 1-year return | -73.47% | +2.00% |
| 5-year return | -96.62% | -91.73% |
| EPS (TTM) | $-0.18 | $-0.64 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $1.58 | $1.55 |
| 52-week low | $0.26 | $0.195 |
| Distance from 52-week high | -77.33% | -34.19% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +1854.22% | +390.20% |
| Average volume | 2.59M | 23.24M |
| Shares outstanding | 189.85M | 72.47M |
| Employees | 128 | 21 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PDSB has outperformed HRTX by 75.5 percentage points over the past year.
About Heron Therapeutics
HRTX stock →Heron Therapeutics, Inc., a commercial-stage biotechnology company, engages in developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.
Healthcare · Biotechnology · 128 employees
About PDS Biotechnology
PDSB stock →PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101, a Versamune HPV, which is in phase II clinical trial for the treatment of head and neck, cervical, anal, vaginal, vulvar, and penile cancers.
Healthcare · Biotechnology · 21 employees
HRTX vs PDSB FAQ
Which is bigger, Heron Therapeutics or PDS Biotechnology?
PDS Biotechnology (PDSB) is larger, with a market capitalization of $73.92M compared with $68.01M for Heron Therapeutics (HRTX).
Which stock has performed better over the past year, HRTX or PDSB?
PDSB returned +2.00% over the past 12 months, compared with -73.47% for HRTX (price return, excluding dividends). Past performance does not predict future results.
Are Heron Therapeutics and PDS Biotechnology in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.